Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Aclaris Therapeutics (Malvern, PA), a preclinical-stage pharmaceutical company focused on topical dermatological therapies, closed a $21M Series A financing. Participants include Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account Access HERE

Thesan Pharmaceuticals (San Clemente, CA), a preclinical biopharmaceutical company focused on dermatological disorders, closed a $16M Series A financing. Participants include Novo Ventures and Novartis Venture Funds. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account Access HERE

Dermira (Redwood City, CA) a clinical-stage pharmaceutical company focused on topical treatments and light therapy for acne and inflammatory skin disease, closed a $42M Series A financing. Participants include Bay City Capital, New Enterprise Associates and Canaan Partners.

Creabilis (Luxembourg) a clinical-stage biotechnology company focused dermatology and inflammatory diseases, closed a $20M Series B financing. Participants include Abbott Biotech Ventures, Neomed and Sofinnova Partners.

AuraSense Therapeutics (Evanston, IL) a development-stage biotechnology company focused on nucleic acid constructs for heart disease, cancer, skin conditions and bacterial infection, closed a $4.5M Series B financing. Participants include Abbott Biotech Ventures.

SARcode (Brisbane, CA) a clinical-stage biopharmaceutical company focused on chronic T-cell mediated inflammation in ophthalmic and dermatologic disease, closed a $44M Series B financing. Participants include Sofinnova Ventures, Rho Ventures, Alta Partners and Clarus Venture Partners. Thanx for your patience as we catch-up.

Kythera Biopharmaceuticals (Calabasas, CA) a clinical-stage biopharmaceutical company focused on aesthetic dermatology, closed a $37.4M Series D financing. Participants include Versant Ventures, Arch Venture Partners, Prospect Venture Partners, Jafco Ventures, Invus Financial Advisors, BBT Capital Management, Altitude Life Science Ventures and Foley Ventures.

Revance Therapeutics (Newark, CA) a clinical-stage biopharmaceutical company developing botulinum toxin type A products focused on topical indications such as lateral canthal lines and hyperhidrosis, closed a $45M Series E financing. Participants include Essex Woodlands Health Ventures, NovaQuest Capital, CNF Investments, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, Pac-Link Ventures and Essex Capital […]

Lotus Tissue Repair (Cambridge, MA) a development-stage biopharmaceutical company focused on dystrophic epidermolysis bullosa and other dermatologic conditions, closed a $26M Series A financing. Participants include Third Rock Ventures.

Delenex (Switzerland) a preclinical-stage biopharmaceutical company focused on CNS and dermatological diseases closed a $19.3M Series A financing, bringing the total round to $38.4M. Participants include Novo Ventures, SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners.

Arbor Pharmaceuticals (Atlanta, GA) a commercial-stage specialty pharmaceutical company atopic dermatitis and otic conditions, closed a $17.5M Series B financing. Participants include Signet Healthcare Partners.

Delenex Therapeutics (Switzerland) a clinical-stage biopharmacetucial company developing therapeutic antibody fragments targeting CNS and dermatological disease, closed a $14M Series A financing. Participants include SV Life Sciences, HBM BioCapital, BioMed Partners and VI Partners.

ReVance Therapeutics (Mountain View, CA) a clinical-stage biopharmaceutical company focused on dermatology and aesthetic medicine, closed a $25.6M Series D financing. Particpants have included Essex Woodlands Health Ventures, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, Bio*One Capital and Pac-Link Venture. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

« Previous Entries  Next Page »

to top of page...